Gregory Kocher, DDS in Laytonville, CA - Dentist

Gregory Kocher, DDS is a Dentist based in Laytonville, California. Gregory Kocher is licensed to practice in California (license number DD030084) and his current practice location is 44900 Highway 101, Suite 4, Laytonville, California. He can be reached at his office (for appointments etc.) via phone at (707) 984-8463.

NPI number for Gregory Kocher is 1316242589 and his current mailing address is Po Box 1758, Laytonville, California. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1316242589.

Contact Information

	Gregory Kocher, DDS
	44900 Highway 101, Suite 4, Laytonville, CA 95454-1758
	(707) 984-8463
	Not Available

Healthcare Provider's Profile

Full Name	Gregory Kocher
Gender	Male
Speciality	Dentist
Location	44900 Highway 101, Laytonville, California
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1316242589
Provider Enumeration Date: 01/20/2011
Last Update Date: 01/20/2011

Medical Identifiers

Medical identifiers for Gregory Kocher such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1316242589	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
122300000X	Dentist	DD030084 (California)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Gregory Kocher is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Gregory Kocher, DDS Po Box 1758, Laytonville, CA 95454-1758 Ph: (707) 984-8463	Gregory Kocher, DDS 44900 Highway 101, Suite 4, Laytonville, CA 95454-1758 Ph: (707) 984-8463

News Archive

Aspirin reduces hereditary colorectal cancer risk

Aspirin reduces colorectal cancer risk by half in individuals at high genetic risk. Preventive efficacy is prolonged for 10-20 years after treatment with aspirin.

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.

Novel cleavage sites for enzyme caspase-3 identified

Investigators at Burnham Institute for Medical Research (Burnham) have identified novel cleavage sites for the enzyme caspase-3 (an enzyme that proteolytically cleaves target proteins). Using an advanced proteomic technique called N-terminomics, Guy Salvesen, Ph.D., professor and director of the Apoptosis and Cell Death Research program of Burnham's NCI-designated Cancer Center, and colleagues determined the cleavage sites on target proteins and found, contrary to previous understanding, that caspase-3 targets α-helices as well as unstructured loops.

athenahealth receives U.S. Patent for its "Practice Management and Billing Automation System"

athenahealth, Inc., a leading provider of internet-based business services to physician practices, today announced that on November 10, 2009, the U.S. Patent and Trademark Office has issued athenahealth a patent entitled, ‘Practice Management and Billing Automation System' (U.S. Patent No. 7,617,116) for its athenaNet® rules engine that is part of the Company's revenue cycle management service, athenaCollectorSM.

Gregory Kocher, DDS - Dentist in Laytonville, CA